Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults

Cancer

Volumn 117, Issue 18, 2011, Pages 4286-4293

  Polishchuk, Alexei L ^a   Dubois, Steven G ^a   Haas Kogan, Daphne ^a   Hawkins, Randall ^a   Matthay, Katherine K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adolescent; adult; metaiodobenzylguanidine (MIBG); neuroblastoma; radiopharmaceutical

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MALE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUTROPENIA; OVERALL SURVIVAL; PAROTITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROID CARCINOMA; THYROID DISEASE; TREATMENT OUTCOME; UNITED STATES; WHOLE BODY RADIATION; XEROSTOMIA;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; NEUROBLASTOMA; RADIOPHARMACEUTICALS; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052493646     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25987     Document Type: Article

References (21)

1. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005; 23: 6459-6465. (Pubitemid 46190236)
2. Hoehner J, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S., A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest. 1996; 75: 659-675. (Pubitemid 26392797)
3. D'Angio GJ, Evans AE, Koop CE., Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1971; 1: 1046-1049.
4. Yu A, Gilman A, Ozkaynak M, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010; 363: 1324-1334.
5. Maris J, Hogarty M, Bagatell R, Cohn S., Neuroblastoma. Lancet. 2007; 369: 2106-2120. (Pubitemid 46935947)
6. Refaat M, Idriss S, Blaszkowsky L., Case report: an unusual case of adrenal neuroblastoma in pregnancy. Oncologist. 2008; 13: 152-156. (Pubitemid 351342579)
7. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK., Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer. 1997; 79: 2028-2035. (Pubitemid 27200389)
8. Kushner B, Kramer K, Modak S, Qin L, Cheung N., Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer. 2010; 116: 3054-3060.
9. Carlin S, Mairs RJ, McCluskey AG, et al. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res. 2003; 9: 3338-3344. (Pubitemid 37082728)
10. Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with [131-I] iodobenzylguanidine. Lancet. 1984; 1: 333-334. (Pubitemid 14185347)
11. DuBois SG, Matthay KK., Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008; 35 (suppl 1): S35-S48.
12. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007; 25: 1054-1060. (Pubitemid 46596756)
13. Shimada H, Chatten J, Newton WA, et al. Histopathologic prognostic factors in neuroblastic tumors. J Natl Cancer Inst. 1984; 73: 405-416.
14. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 3. Washington, DC: National Institute of Health, National Cancer Institute; 2006.
15. Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998; 16: 229-236. (Pubitemid 28041603)
16. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med. 2001; 42: 1713-1721. (Pubitemid 33131334)
17. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11: 1466-1477. (Pubitemid 23228250)
18. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK., Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003; 25: 543-547. (Pubitemid 36830702)
19. DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004; 22: 2452-2460. (Pubitemid 41115404)
20. Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with neuroblastoma after combined treatment with 131I- metaiodobenzylguanidine. Cancer. 2003; 97: 1332-1338. (Pubitemid 36237321)
21. Kaye JA, Warhol MJ, Kretschmar C, Landsberg L, Frei E 3rd. Neuroblastoma in adults. Three case reports and a review of the literature. Cancer. 1986; 58: 1149-1157. (Pubitemid 16046952)